Intellia Therapeutics' CRISPR-based treatment for a rare swelling condition, lonzo-z, has passed a Phase 3 trial and is expected to receive approval from the U.S. Food and Drug Administration. The one-time treatment successfully reduced attacks by 87%. This is the first time the company has reported such successful results. The company believes this could be a significant breakthrough in medicine.